SOLARA

Solara Active Pharma Sciences Limited

Active pharmaceutical ingredients and specialty chemicals manufacturer

Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals

Ask AI

Key metrics

Price as of 2026-10-19

Stock price
₹645.65
Market cap
3,109 Cr
Stock P/E
84.2
P/B
2.17
Dividend yield
0.3%
ROE (FY26)
-0.6%
ROCE (FY26)
4.5%
Operating margin (FY26)
6.4%
Debt / equity (FY26)
0.53
OCF / EBITDA (FY26)
81.9%
OCF / EBITDA (3Y)
159.3%

Full years shown; sign in free for the trailing twelve months. Learn about these metrics →

Price & valuation

Share price and valuation multiples (P/E, P/B and more) over time.

Loading price history…

Compare with peers

Loading peers…

What you need to know

Solara Active Pharma Sciences (Solara) makes active pharmaceutical ingredients (APIs), the drug substances inside medicines, for drugmakers worldwide, with most sales to regulated markets.

Company snapshot

69thBy market cap

Ranked among 119 companies in Pharmaceuticals.

What we see

Positives
  • ✓159% of operating profit came in as cash over the last three years — profits are backed by real cash.
Concerns
  • ✗Net margin is negative — the company is spending more than it earns right now.
2 more signals from the filings.Sign in free to see them all

Statement tables · Consolidated

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Amounts in ₹ Cr · tap + to expand rows

Quarterly results

Quarterly · ₹ Cr · tap + rows to expand

MetricDec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026Sept 2026
Sales249 Cr299 Cr363 Cr347 Cr300 Cr273 Cr319 Cr314 Cr349 Cr387 Cr382 Cr417 Cr
Operating expenses (approx.)410 Cr290 Cr322 Cr286 Cr243 Cr228 Cr262 Cr279 Cr312 Cr330 Cr320 Cr341 Cr
EBITDA-162 Cr10 Cr42 Cr61 Cr58 Cr45 Cr57 Cr35 Cr37 Cr58 Cr62 Cr77 Cr
OPM %-65.0%3.3%11.5%17.7%19.2%16.6%17.9%11.1%10.7%14.9%16.2%18.4%
Other income0.45 Cr2 Cr0.56 Cr0.32 Cr1 Cr6 Cr0.98 Cr0.49 Cr0 Cr5 Cr3 Cr0.54 Cr
Interest25 Cr31 Cr31 Cr28 Cr27 Cr29 Cr24 Cr21 Cr22 Cr28 Cr22 Cr18 Cr
Depreciation26 Cr25 Cr25 Cr25 Cr25 Cr24 Cr24 Cr24 Cr26 Cr26 Cr27 Cr27 Cr
Profit before tax-275 Cr-167 Cr-13 Cr8 Cr8 Cr-2 Cr11 Cr-10 Cr-17 Cr10 Cr16 Cr28 Cr
Tax %0.0%-53.3%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net profit-275 Cr-255 Cr-13 Cr8 Cr8 Cr-2 Cr11 Cr-10 Cr-17 Cr10 Cr16 Cr28 Cr
EPS (₹)₹-76.49₹-70.93₹-3.50₹2.54₹2.03₹-0.93₹2.46₹-2.36₹-3.98₹2.20₹3.52₹5.92

Profit & loss (annual)

Annual · last column is TTM · ₹ Cr · tap + to expand

MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales1,387 Cr1,322 Cr1,617 Cr1,268 Cr1,444 Cr1,289 Cr1,284 Cr1,369 CrSign in free for the trailing twelve months
Operating expenses (approx.)1,166 Cr1,062 Cr1,231 Cr1,188 Cr1,310 Cr1,384 Cr1,077 Cr1,182 CrSign in free for the trailing twelve months
EBITDA221 Cr259 Cr386 Cr80 Cr134 Cr-95 Cr206 Cr187 CrSign in free for the trailing twelve months
OPM %15.9%19.6%23.9%6.3%9.3%-7.4%16.1%13.6%Sign in free for the trailing twelve months
Other income12 Cr28 Cr29 Cr20 Cr23 Cr5 Cr8 Cr6 CrSign in free for the trailing twelve months
Interest82 Cr78 Cr84 Cr75 Cr90 Cr105 Cr115 Cr95 CrSign in free for the trailing twelve months
Depreciation83 Cr94 Cr109 Cr112 Cr111 Cr103 Cr99 Cr100 CrSign in free for the trailing twelve months
Profit before tax58 Cr115 Cr222 Cr-91 Cr-45 Cr-488 Cr0.54 Cr-7 CrSign in free for the trailing twelve months
Tax %-2.9%0.3%0.1%36.0%50.4%-16.1%0.0%0.0%Sign in free for the trailing twelve months
Net profit59 Cr115 Cr221 Cr-58 Cr-22 Cr-567 Cr0.54 Cr-7 CrSign in free for the trailing twelve months
EPS (₹)₹21.77₹44.29₹69.00₹-16.18₹-6.16₹-157.62₹0.14₹-1.68Sign in free for the trailing twelve months
Dividend payout %——8.9%———0.0%—Sign in free for the trailing twelve months
Sign in free for the trailing twelve months

The latest four quarters added up, next to each full year

Balance sheet

Annual · ₹ Cr · tap + rows to expand

MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity capital26 Cr27 Cr36 Cr36 Cr36 Cr36 Cr40 Cr45 Cr
Reserves930 Cr1,059 Cr1,553 Cr1,489 Cr1,464 Cr898 Cr1,054 Cr1,208 Cr
Borrowings439 Cr587 Cr516 Cr1,025 Cr1,001 Cr1,000 Cr776 Cr665 Cr
Other liabilities560 Cr477 Cr505 Cr401 Cr395 Cr414 Cr359 Cr413 Cr
Total liabilities1,960 Cr2,154 Cr2,614 Cr2,953 Cr2,899 Cr2,351 Cr2,232 Cr2,333 Cr
Fixed assets (net)720 Cr849 Cr911 Cr899 Cr921 Cr858 Cr739 Cr793 Cr
CWIP40 Cr40 Cr88 Cr239 Cr238 Cr256 Cr280 Cr205 Cr
Investments30 Cr91 Cr26 Cr25 Cr26 Cr4 Cr4 Cr5 Cr
Loans & advances2 Cr52 Cr2 Cr52 Cr33 Cr0.34 Cr0.02 Cr0.03 Cr
Inventories220 Cr280 Cr295 Cr576 Cr558 Cr360 Cr318 Cr318 Cr
Trade receivables289 Cr227 Cr484 Cr490 Cr537 Cr349 Cr327 Cr439 Cr
Cash & bank76 Cr56 Cr198 Cr46 Cr9 Cr8 Cr4 Cr4 Cr
Other assets582 Cr559 Cr610 Cr627 Cr578 Cr516 Cr561 Cr569 Cr
Total assets1,960 Cr2,154 Cr2,614 Cr2,953 Cr2,899 Cr2,351 Cr2,232 Cr2,333 Cr

Cash flows

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from operating activity166 Cr244 Cr155 Cr-242 Cr156 Cr109 Cr213 Cr153 Cr
Cash from investing-116 Cr-359 Cr-106 Cr-243 Cr-81 Cr-4 Cr-37 Cr-99 Cr
Cash from financing-23 Cr95 Cr92 Cr334 Cr-113 Cr-106 Cr-180 Cr-54 Cr
Net cash flow27 Cr-20 Cr142 Cr-151 Cr-38 Cr-0.29 Cr-4 Cr0.53 Cr
Free cash flow (OCF − Capex)107 Cr-25 Cr-19 Cr-451 Cr45 Cr68 Cr173 Cr100 Cr

Ratios

MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
ROCE %10.0%11.5%14.5%-0.6%1.8%-19.8%6.2%4.5%
ROE %6.2%10.5%13.9%-3.8%-1.5%-60.6%0.0%-0.6%
Debtor days76631091411359993117
Inventory days110170157244262173199172
Days payable122131165120144150156148
Cash conversion cycle64101101264254121136140
OCF / EBITDA %75.3%94.1%40.3%-302.7%116.7%—103.2%81.9%
OCF / EBITDA % (3 years)——65.4%21.7%11.6%n.m.195.1%159.3%
Debt / equity0.460.540.320.670.671.070.710.53
Current ratio1.000.921.341.161.080.630.770.96
Net debt / EBITDA1.652.040.8212.237.41—3.743.53